Release-notes

1. In-depth revision of the hematology chapter.
2. Addition of a section on thalassemia.
3. Correction of the CKD table (indications for reference in nephrology, addition of the KFRE score).
4. New definition of obesity 2025.
5. Addition of the EHMRG score in the heart failure table, decompensated heart failure section.
6. Multiple minor corrections.

1. Minor corrections.
2. Modification to the table of contents.

Addition of the 2024 TNM table for lung cancer.

Addition of a section on the treatment of secondary hypertension.

Multiple minor corrections (eosinophilia, cirrhosis, tuberculosis…).

1. Multiple minor corrections to various pages (Melanoma, Lung Cancer, Pulmonary Hypertension, Hypercalcemia, Hypertension, etc.).
2. Corrections to certain figures (Stroke, Hyperkalemia).
3. Update to the Drugs section (Appendix).

1. Content updated with new guidelines
2. Other minor adjustments

• Significant revision of the respirology chapter.
• Changes to the myasthenia gravis section (addition of the MGFA classification).
• Addition of Lomitapide to the pharmacological appendix.

• Update on Post-Myocardial Infarction Driving Guidelines (CCS 2023)
• Inclusion of the EHRA Symptom Severity Scale in the atrial fibrillation section.
• Minor modifications to several pages.
• Addition of Omvoh in the pharmacological appendix.
• Over 100 new references.

• Update to the Osteoporosis page according to the new recommendations from Osteoporosis Canada 2023.

• Multiple minor corrections in several chapters.

• New medications in Appendix: abrocitinib, deucravacitinib, romosozumab.

• Antiphospholipid Syndrome : added the ACR-EULAR 2023 diagnostic criteria
• Minor edits
• Bug fixes

• Completed English translation for the newest edition.
• Bugs and minor fixes.

• New English edition (completed).
• New references.
• Integration of new criteria for infective endocarditis (Duke-ISCVID 2023).
• Minor edits.

• New edition completely updated after 8 months of work with many new co-authors and collaborators.
• New pages: acne, myelodysplastic neoplasms.
• New sections on preseptal cellulitis, orbital cellulitis, tick-borne viral encephalitis, and atrophic gastritis.
• New drugs in the pharmacological appendix: finerenone, tirzepatide.
• Over a hundred new references.
• Technical fixes and improvements

• New Chest X-Ray Abnormalities page.
• New Monkeypox page.
• Updated direct oral anticoagulants in the perioperative setting section (ACCP and ESC 2022).
• Added ranolazine to the Drugs section (new sodium current inhibitor class)
• Multiple minor edits to all chapters.
• More than 50 new references

• Updated recommendations for the prevention of contrast nephropathy in the ARF and CRF pages (according to CAR 2022)

• New table on primary immunodeficiency, with the collaboration of Drs Hugues Allard-Chamard and Philippe Bilodeau.
• Added a section on malignant catatonia to the Non-infectious Hyperthermia page.
• Important corrections in gastroenterology and respirology.
• Updated COVID-19 section.
• Added Edmonton Obesity Staging System to obesity page.
• Multiple minor fixes in all chapters.
• More than 100 new references.

• COVID update
• Minor edits in all chapters.
• New medication : Bimekizumab (Bimzelx)

• Significant page edits: COVID-19, thyroid nodules, lung and thyroid cancer, etc.
• Minor edits in all chapters.
• New drugs: Adtralza (tralokinumab), Breztri Aerosphere (formoterol + budesonide + glycopyrronium), Effient (Prasugrel), Ilymia (tildrakizumab), Leqvio (inclisiran), Saphnelo (Anifrolumab).
• Over 100 new references.

• Revised General internal medicine and Neurology chapters.
• Canadian Heart Failure and Dyslipidemia Guidelines updates integrated in the text.
• Minor revisions to several chapters.
• New drugs in the Drugs section (Appendix).
• New collaborator: Prof. Michel Cauchon.
• More than 100 new references.

• New section: IgG4-Related Disease in General Internal Medicine chapter, made in collaboration with Drs Harold Bernatchez et Hugues Allard-Chamard.
• Addition of tenecteplase in Thrombolysis in Stroke.
• Addition of the Clinical Progression Scale in COVID-19 section.
• Addition of the De Bakey classification in Aortic Dissection section.
• Minor edits to all chapters.
• New drugs in the Drugs section: Guselkumab (Tremfya), indacatérol + mometasone (Atectura breezhaler), indacaterol + glycopyrronium + mometasone (Enerzair breezhaler).
• More than 100 new references.

• COVID-19 section updates (treatment)
• Modification to acetaminophen poisoning section
• Minor edits to all chapters
• More than 100 new references